Summit Global Investments Has $9.66 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Summit Global Investments grew its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 75.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 729,200 shares of the company's stock after purchasing an additional 313,642 shares during the quarter. Summit Global Investments' holdings in Takeda Pharmaceutical were worth $9,655,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TAK. Pathstone Holdings LLC raised its holdings in Takeda Pharmaceutical by 1.0% in the 3rd quarter. Pathstone Holdings LLC now owns 430,676 shares of the company's stock worth $6,124,000 after acquiring an additional 4,280 shares during the period. Caprock Group LLC grew its position in shares of Takeda Pharmaceutical by 7.7% in the third quarter. Caprock Group LLC now owns 34,304 shares of the company's stock valued at $488,000 after purchasing an additional 2,454 shares during the last quarter. Advisors Asset Management Inc. increased its stake in shares of Takeda Pharmaceutical by 41.4% in the third quarter. Advisors Asset Management Inc. now owns 51,226 shares of the company's stock worth $728,000 after purchasing an additional 14,992 shares during the period. Smithfield Trust Co lifted its position in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Takeda Pharmaceutical by 17.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company's stock valued at $2,661,000 after purchasing an additional 27,628 shares during the period. Institutional investors own 9.17% of the company's stock.

Remove Ads

Takeda Pharmaceutical Stock Performance

TAK traded down $0.05 during midday trading on Wednesday, reaching $15.00. The company's stock had a trading volume of 1,578,187 shares, compared to its average volume of 1,794,727. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.31. The stock has a market cap of $47.71 billion, a P/E ratio of 37.49, a PEG ratio of 0.24 and a beta of 0.46. The company has a fifty day simple moving average of $14.04 and a 200 day simple moving average of $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.